Lantern Pharma, Inc. (LTRN)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Lantern Pharma, Inc. (LTRN)
Go deeper and ask any question about LTRN
Company Performance
Current Price
as of Sep 13, 2024$4.02
P/E Ratio
N/A
Market Cap
$43.27M
Description
Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-100, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.
Metrics
Overview
- HQDallas, TX
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerLTRN
- Price$4.02+6.07%
Trading Information
- Market Cap$43.27M
- Float74.46%
- Average Daily Volume (1m)49,653
- Average Daily Volume (3m)59,656
- EPS-$1.65
Company
- RevenueN/A
- Rev Growth (1yr)N/A
- Net Income-$4.96M
- Gross MarginN/A
- EBITDA MarginN/A
- EBITDA-$5.36M
- EV$17.20M
- EV/RevenueN/A
- P/EN/A
- P/SN/A
Documents
SEC Filings
Earnings Calls
Factset Street Account